The above results reveal that compound EDA-71 is an inhibitor of the transcription factor NF-κB, and its effect was more pronounced in MDA-MB-231 triple-negative breast cancer (Figure 8). The gene discussed is NFKB1; the disease is triple-negative breast carcinoma.